CD274 and neoplasm: Taken together, these data indicate that combinatorial treatment activates NK-, T- and myeloid-cells while simultaneously disrupting the inhibitory PD-1/PD-L1 pathway and reducing the accumulation of suppressive Mo-MDSC within the tumor microenvironment.